Prenetics Bags $48 Mn to Enhance AI-powered Cancer Detection

Insighta, the joint venture between Prenetics and Tencent, focuses on combining artificial intelligence and genetic testing to detect cancer before symptoms appear.

Hong Kong-based healthtech Platform Prenectis has raised $48 Mn in equity funding aimed at boosting its AI Cancer Detection platform, Insighta.

The funding established its partnership with Tencent, which has invested $30 Mn in funding.

Insighta, the joint venture between Prenetics and Tencent, focuses on combining artificial intelligence and genetic testing to detect cancer before symptoms appear.

The platform analyzes blood samples for minute genetic signatures indicative of cancer, aiming for earlier and more accurate detection.

Prenetics CEO Danny Yeung described their mission as “building tools that can spot cancer before people even know they’re unwell,” emphasising the potential impact of early detection.

The new fund is also expected to support the expansion of Prenetics’ wellness brand IM8, which includes wearable health solutions, supplement products, and consumer health services.

The company intends to use the capital both to broaden its clinical diagnostics reach and to build further scale for its consumer health offerings.

While the AI cancer detection project is the principal focus, Prenetics will also continue investing in INM8’s ecosystem. Those expansion efforts include boosting infrastructure, clinical validations, and regulatory advancement in key markets.

Moreover, the company is also developing AI tools that analyze blood samples for traces of cancer DNA, which can facilitate early detection by enabling physicians to detect small genetic changes in blood.

Stay tuned for more such updates on Digital Health News